Table 3

Clinical-pathological prognostic features of disease
Prevalent (n = 76) vs. Symptomatic (n = 130) P value OR adjusted by tumor size
Mean age 56.8 ± 0.65 vs. 56.3 ± 1.14 N.S. 1.01 (0.98-1.03)
Mean size (cm) 1.64 ± 0.15 vs. 2.68 ± 0.15 p < 0.001 --
Lymph node positive 25% vs. 48.5% p < 0.001 0.54 (0.27-1.08)
Poorly differentiated tumors 32.1% vs. 39.7% N.S. 0.55 (0.29-1.04)
ER positive 87.5% vs. 57.4% p < 0.001 4.56 (1.98-10.52)
PR positive 70.3% vs. 36.4% p < 0.001 3.65 (1.88-7.08)
In situ carcinomas 13% vs. 1.5% p < 0.001 8.30 (1.70-40.31)
Apoptosis 42.5% vs. 38.5% N.S. 1.45 (0.67-3.16)
Bcl-2 75.4% vs. 62.7% N.S. 1.52 (0.75-3.06)
c-erb-B2 7.4% vs. 26.3% p < 0.01 0.59 (0.31-0.90)
Ki67 38.5 vs. 52.5% N.S. 0.64 (0.34-1.22)
Delay Diagnosis-treatment (>30 days) 64.5% vs. 55% N.S. 1.51 (0.81-2.81)

Redondo et al.

Redondo et al. BMC Cancer 2012 12:604   doi:10.1186/1471-2407-12-604

Open Data